公开(公告)号：US11660328B2

公开(公告)日：2023-05-30

申请号：US16761606

申请日：2018-11-05

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Clark Pan ,  Angela Norton ,  Bettina Strack-Logue ,  Clément Olivier

IPC: A61K38/26 ,  A61K47/68 ,  A61P1/00

CPC classification number: A61K38/26 ,  A61K47/6811 ,  A61P1/00

Abstract: GLP-2 analogs, such as teduglutide, and fusion proteins of GLP-2 with immunoglobulin are administered before, during or after surgery, particularly resection of the small intestine. When short bowel syndrome develops after surgical resection of the small intestine, parenteral nutrition is usually necessary to compensate for reduced absorption of water and nutrients across the small intestine. GLP-2 analogs and GLP-2 fusion proteins promote growth of small intestine, improve nutrient absorption and can reduce the need for parenteral nutrition after surgery.

公开(公告)号：US20240034779A1

公开(公告)日：2024-02-01

申请号：US18482522

申请日：2023-10-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Sebastien Vallee ,  Madhusudan Natarajan ,  Rizwana Islam ,  Muthuraman Meiyappan ,  Angela Norton ,  Niksa Kastrapeli ,  Christophe Blanchetot ,  Christophe Steyaert

IPC: C07K16/18 ,  C12N15/63 ,  A61P7/00

CPC classification number: C07K16/18 ,  C12N15/63 ,  A61P7/00 ,  C07K2317/565 ,  C07K2317/52 ,  C07K2317/92 ,  C07K2317/14

Abstract: Antibodies that specifically bind to complement factor D in a pH sensitive manner, are described, as well as methods of making and using such antibodies.